HomeNewsIndiaAmitabh Kant writes: The power of collectivised solutions in fighting a COVID-19 pandemic

Amitabh Kant writes: The power of collectivised solutions in fighting a COVID-19 pandemic

How an empowered group has worked with NGOs, private sector, and international organisations to create a unified response system

May 22, 2020 / 09:17 IST
Story continues below Advertisement
File image
File image

Amitabh Kant

Everybody agrees that we are living through unprecedented times. The nature and scale of the crisis that the novel coronavirus, or COVID-19, pandemic has unfolded is unparalleled. In such a scenario, solutions are unlikely to come from past experiences or best practices. The biggest source of strength now is the partnerships we have built over the years. The situation at hand calls for stakeholders to come together, work side by side, channelise efforts, and support each other. This, precisely, is what one of the empowered groups (EG) created by the government for comprehensive action and integrated response to contain the pandemic has been doing since it was formed at the end of March.

Story continues below Advertisement

The mandate is to coordinate with three key groups of stakeholders -- NGOs, private sector, and international development organisations -- and help them in charting the best course of response action. The fight against COVID-19, since its start, needed as many hands as were available. The job was too big for the government to handle alone.

The strategy was to leverage vertical and horizontal partnerships: the vertical partnerships that the stakeholders have built within their organisations (for instance, multiple agencies in the UN system) and the horizontal partnerships which the government has institutionalised with the stakeholders (for example, NGO Darpan). The empowered group itself is a partnership, as its members are from eight different government ministries/organisations.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show